NANODIAMONDS ENCAPSULATED IN NANOFIBERS AS A NEW STRATEGY FOR MICRORNA-BASED THERAPY OF PROSTATE CANCER

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378041%3A_____%2F19%3A00522949" target="_blank" >RIV/68378041:_____/19:00522949 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61388971:_____/19:00522949 RIV/68407700:21720/19:00340546

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

NANODIAMONDS ENCAPSULATED IN NANOFIBERS AS A NEW STRATEGY FOR MICRORNA-BASED THERAPY OF PROSTATE CANCER

Popis výsledku v původním jazyce

Given the miRNA-34 family role as tumor suppressor in cancer, it was showed that using miRNA-34a as a new anticancer agent has a great therapeutic potential. Unfortunately, biopharmaceutical issues, rapid degradation in biological fluids, poor uptake into cells and not specific distribution into the body, prevent the use of wildtype non-coding RNA by systemic administration. To overcome these limits, in our previous study we developed a new therapeutic concept based on nanotechnology delivery of miRNA-34a into prostate cancer using fluorescent nanodiamond particles coated with polyethylenimine. In the current study, in order to achieve a more conservative, stable and controlled release of miRNA-34a, we designed a system based on nanodimaonds- miRNA34a complexes encapsulated into nanofibers. We successfully encapsulate nanodiamonds into fibers of polycaprolactione, a biodegradable polymer with a slow degradation rate and a high cellular adhesion, using an electropsinning process. We cultivated prostate cancer cells (PC3 and DU145) on nanofibers scaffolds and we analyzed the presence of nanodiamonds in cells using confocal microscopy. Moreover, in these prostate cancer cell lines we observed a replacement of miRNA-34a via real-time PCR and a decreased viability testing the metabolic activity. Our preliminar results suggest a higher increased and stable mid-term replacement of oncosuppressor miRNA-34a in prostate cancer when the nanodiamonds-miRNA complexes are delivered encapsulating them in nanofibers. Therefore we provided an effective strategy for cancer therapy ready to be tested for in vivo experiments.

Název v anglickém jazyce

NANODIAMONDS ENCAPSULATED IN NANOFIBERS AS A NEW STRATEGY FOR MICRORNA-BASED THERAPY OF PROSTATE CANCER

Popis výsledku anglicky

Given the miRNA-34 family role as tumor suppressor in cancer, it was showed that using miRNA-34a as a new anticancer agent has a great therapeutic potential. Unfortunately, biopharmaceutical issues, rapid degradation in biological fluids, poor uptake into cells and not specific distribution into the body, prevent the use of wildtype non-coding RNA by systemic administration. To overcome these limits, in our previous study we developed a new therapeutic concept based on nanotechnology delivery of miRNA-34a into prostate cancer using fluorescent nanodiamond particles coated with polyethylenimine. In the current study, in order to achieve a more conservative, stable and controlled release of miRNA-34a, we designed a system based on nanodimaonds- miRNA34a complexes encapsulated into nanofibers. We successfully encapsulate nanodiamonds into fibers of polycaprolactione, a biodegradable polymer with a slow degradation rate and a high cellular adhesion, using an electropsinning process. We cultivated prostate cancer cells (PC3 and DU145) on nanofibers scaffolds and we analyzed the presence of nanodiamonds in cells using confocal microscopy. Moreover, in these prostate cancer cell lines we observed a replacement of miRNA-34a via real-time PCR and a decreased viability testing the metabolic activity. Our preliminar results suggest a higher increased and stable mid-term replacement of oncosuppressor miRNA-34a in prostate cancer when the nanodiamonds-miRNA complexes are delivered encapsulating them in nanofibers. Therefore we provided an effective strategy for cancer therapy ready to be tested for in vivo experiments.

Druh

D - Stať ve sborníku

CEP obor

—

OECD FORD obor

30404 - Biomaterials (as related to medical implants, devices, sensors)

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

NANOCON 2018 - Conference Proceedings, 10th Anniversary International Conference on Nanomaterials - Research and Application

ISBN

978-808729489-5

ISSN

—

e-ISSN

—

Počet stran výsledku

6

Strana od-do

348-353

Název nakladatele

Tanger Ltd.

Místo vydání

Ostrava

Místo konání akce

Brno

Datum konání akce

17. 10. 2018

Typ akce podle státní příslušnosti

EUR - Evropská akce

Kód UT WoS článku

000513131900060